Phase II Study of Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer.

Trial Profile

Phase II Study of Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2016

At a glance

  • Drugs Temozolomide (Primary)
  • Indications Small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Feb 2012 Actual patient number 92 added as reported by ClinicalTrials.gov.
    • 08 Feb 2012 Planned end date changed from 1 Aug 2012 to 1 Aug 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top